

Financial Tear Sheet

Corporate Profile

TherapeuticsMD, Inc. is an innovative healthcare company focused on developing and commercializing products exclusively for women. With its SYMBODA™ technology, TherapeuticsMD is developing advanced hormone therapy pharmaceutical products to enable delivery of bio-identical hormones through a variety of dosage forms and administration routes. The company's clinical development pipeline includes multiple hormone therapy products at various stages of clinical development. The company also manufactures and distributes branded and generic prescription prenatal vitamins under the vitaMedMD® and BocaGreenMD® brands. More information is available at the following websites: vitamedmdrx.com and bocagreenmd.com .

Stock Performance

TXMD (Common Stock)

Exchange	NYSE (US Dollar)
Price	\$6.04
Change (%)	0.00 (0.00%)
Volume	0
52 Week Low	\$3.50
Market Cap	\$1,232,323,938
Rolling EPS	-0.45
PE Ratio	0
Shares Outstanding	204,027,142

Data as of 08/21/17 8:00 p.m. ET



Recent Headlines & Events

- 08/16/17  
TherapeuticsMD Announces Publication of Manuscript on the Women's Health Initiative Observational Study of Vaginal Estrogen Use in Postmenopausal Women
- 08/10/17  
TherapeuticsMD Provides TX-004HR Regulatory Update
- 08/03/17  
TherapeuticsMD Announces Second Quarter 2017 Financial Results

There are currently no events scheduled.

SEC Filings

Filing Date	Form
08/10/17	8-K
08/03/17	10-Q
08/03/17	8-K
07/17/17	8-K

Corporate Governance

EXECUTIVE TEAM

- |                   |   |
|-------------------|---|
| Robert G. Finizio | Chief Executive Officer, Co-Founder, and Director |
| John Milligan     | President   |
| Dan Cartwright    | Chief Financial Officer                           |
| Dawn Halkuff      | Chief Commercial Officer                          |

CLINICAL TEAM

- |                                 |                                       |
|---------------------------------|---------------------------------------|
| Brian Bernick, M.D., F.A.C.O.G. | Co-Founder and Chief Clinical Officer |
| Sebastian Mirkin, M.D.          | Chief Medical Officer                 |
| Julia Amadio                    | Chief Product Officer                 |
| Marlan Walker, J.D.             | General Counsel                       |
| Christine Miller, Pharm.D.      | Chief Regulatory and Quality Officer  |

OPERATIONS TEAM

- |                     |                                    |
|---------------------|------------------------------------|
| Mitchell Krassan    | Chief Strategy Performance Officer |
| Jason Spitz         | Vice President of Marketing        |
| Christian Bloomgren | Vice President of Sales            |
| Michael Donegan     | Vice President of Finance          |

Ownership Summary

Shareholders

	Holders	Value (\$MM)	% O/S	Shares
Institution	189	1,079.46	100.6	205,205,849
Mutual Fund	218	591.96	54.6	111,438,971
Insider *	3	112.55	9.3	18,946,559

\*Insider values reflect direct beneficial ownership.  
Data Provided by Thomson Reuters

Top Holders

	Shares Held	% O/S	Share Change	Filing Date
Fidelity Management & Research Company	25,601,770	12.6	-3,054,461	06/30/17
Finizio (Robert G)	20,643,559	10.1	-145,000	04/17/17
T. Rowe Price Associates, Inc.	20,025,126	9.8	-5,547,160	06/30/17
The Boston Company Asset Management, LLC	19,532,426	9.6	1,689,632	06/30/17
BlackRock Institutional Trust Company, N.A.	10,518,405	5.2	287,897	06/30/17
Franklin Advisers, Inc.	10,260,962	5.0	-75,356	06/30/17
The Vanguard Group, Inc.	10,231,081	5.0	429,211	06/30/17
Smith (Robert J)	10,056,770	4.9	2,199,265	04/17/17
JP Morgan Asset Management	7,905,984	3.9	1,161,114	06/30/17
Bernick (Brian A)	6,827,371	3.4	-101,128	04/17/17

Data provided by Nasdaq. Minimum 15 minutes delayed. View [Attributions and Sources](#)